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CHAPTER 7 
Role of post-translational modifications in 
modulating the structure, function and toxicity of 
a-synuclein: implications for Parkinson’s disease 
pathogenesis and therapies 
Abid Oueslati†, Margot Fournier† and Hilal A. Lashuel 
Laboratory of Molecular Neurobiology and Neuroproteomics, Brain Mind Institute, The Ecole Polytechnique F�ed�erale 
de Lausanne (EPFL), Lausanne, Switzerland 
Abstract: A better understanding of the molecular and cellular determinants that influence the pathology 
of Parkinson’s disease (PD) is essential for developing effective diagnostic, preventative and therapeutic 
strategies to treat this devastating disease. A number of post-translational modifications to a-syn are present 
within the Lewy bodies in the brains of affected patients and transgenic models of PD and related disorders. 
However, whether disease-associated a-syn post-translational modifications promote or inhibit a-syn 
aggregation and neurotoxicity in vivo remains unknown. Herein, we summarize and discuss the major 
disease-associated post-translational modifications (phosphorylation, truncation and ubiquitination) and 
present our current understanding of the effect of these modifications on a-syn aggregation and toxicity. 
Elucidating the molecular mechanisms underlying post-translation modifications of a-syn and the 
consequences of such modifications on the biochemical, structural, aggregation and toxic properties of the 
protein is essential for unravelling the molecular basis of its function(s) in health and disease. Furthermore, 
the identification of the natural enzymes involved in regulating the post-translational modifications of 
a-synuclein will yield novel and more tractable therapeutic targets to treat PD and related synucleinopathies. 
Keywords: a-synuclein; post-translationnal modification; phosphorylation; truncation; ubiquitination 
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therapeutic strategies to treat this devastating dis­
ease. Current strategies offer little more than tran­
sient symptomatic relief. Evidence from genetics, 
pathology, animal modelling, cell culture and 
in vitro biochemical and biophysical studies supports 
the hypothesis that a-synuclein (a-syn) plays a cen­
tral role in the pathogenesis of PD and several other 
neurodegenerative diseases, collectively referred to 
as ‘synucleinopathies’. Although  a-syn has emerged 
as a viable therapeutic target, the molecular and 
cellular determinants involved in initiating and/or 
propagating a-syn aggregation and toxicity and the 
relationship between these processes and disease 
progression remain poorly understood. In PD, sev­
eral post-translational modifications of a-syn are 
associated with the formation of Lewy bodies (LB) 
in the brains of affected patients and of transgenic 
(TG) models of PD and other synucleinopathies. 
However, whether disease-associated a-syn post­
translational modifications such as phosphorylation, 
truncation, ubiquitination and nitration promote or 
inhibit a-syn aggregation and neurotoxicity in vivo 
remains unknown. This understanding is critical to 
elucidate the role of a-syn in the pathogenesis of PD 
and to develop therapeutic strategies for PD. There­
fore, characterizing the molecular mechanisms 
underlying post-translation modifications of a-syn 
and the consequences of such modifications on the 
biochemical, structural, aggregation and toxic prop­
erties of the protein is essential for unravelling the 
molecular basis of its function(s) in health and dis­
ease. Furthermore, identification of the natural 
enzymes (e.g. kinases and phosphatases) involved 
in regulating a-syn post-translational modifications 
will yield novel and more effective therapeutic tar­
gets to treat PD and related synucleinopathies. 
Structural and biochemical properties of a-syn 
The sequence of a-syn can be divided into three 
domains with different features (Fig. 1a). The 
Fig. 1. a-syn structure and molecular mechanism of its oligomerization and fibrillogenesis. (a) Schematic representation of a-syn, 
where the N-terminal repeats (KTKEGV) are represented in blue; they partially overlap with the core domain (white). The 
pathogenic variants associated with familial forms of PD alter the N-terminus of a-syn and enhance its propensity to form 
protofibrils (A30P) or mature fibrils (E46K and A53T). (b) Illustration of the molecular steps involved in a-syn oligomerization 
and fibrillogenesis leading to Lewy body formation (adapted from Lashuel and Lansbury, 2006). 
Author's personal copy
117 
N-terminal region, comprising amino acids 1–60, 
contains four 11 residue imperfect repeats with a 
highly conserved hexameric motif (KTKEGV). 
The central region, comprising residues 61–95, 
also known as the non-amyloid component region 
(NAC), is composed of predominantly hydropho­
bic residues and is essential for a-syn fibrillization 
and LB formation. The C-terminal region (residues 
96–149) is highly enriched in acidic (glutamate and 
aspartate) and proline residues and exists in a dis­
ordered conformation in the monomeric as well as 
the oligomeric and fibrillar forms of a-syn (Bertini 
et al., 2007; Wu et al., 2008). The C-terminus of a­
syn has been proposed to function as a solubilizing 
domain and contributes to a-syn’s thermostability.  
The C-terminal region of a-syn has been implicated 
in the majority of a-syn interactions with proteins 
(Cherny et al., 2004; Fernandez et al., 2004; 
Giasson et al., 2003; Jensen et al., 1999), metal 
ions (Brown, 2007; Paik et al., 1999) and other 
ligands (e.g. dopamine and polyamines) (Hoyer 
et al., 2004) and contains the majority of post-trans­
lational modification sites. a-Synuclein interactions 
with the microtubule-associated protein tau, brain-
specific p25a and FKBP-type peptidyl-prolyl 
cis–trans isomerases have all been mapped to 
the C-terminal region encompassing residues 
110–140, suggesting that the C-terminus of a-syn 
plays a critical role in modulating the stability, 
structure, aggregation and function of the protein 
in vivo (Kim et al., 2002). 
In solution, a-syn (wild type, WT, A30P, E46K 
and A53T) exists as an ensemble of disordered 
conformations (Weinreb et al., 1996). However, 
in the presence of lipids, the N-terminal region 
adopts an a-helical conformation. Several factors 
have been shown to contribute to triggering the 
oligomerization and fibril formation by a-syn, 
including high protein concentrations, mutations, 
post-translational modifications and interactions 
with specific metals (Brown, 2007; Paik et al., 
1999) and small molecules (Hoyer et al., 2004). 
Fibril formation by a-syn proceeds through series 
of discrete oligomeric intermediates, known as 
protofibrils of different sizes and morphologies, 
including spherical, annular and chain-like struc­
tures (Fig. 1b). 
The rate of a-synuclein fibrillization is affected 
by several factors that may be relevant to PD 
Several post-translational covalent modifications 
have been described for a-syn, including serine 
and tyrosine phosphorylation, ubiquitination, 
nitration, enzymatic cross-linking (e.g. tissue 
transglutaminase) and C-terminal truncation, 
some of which correlate well with PD (Fig. 2). In 
this section we will review the most commonly 
observed post-translational disease-associated 
modifications. We will present an overview of 
the current understanding of their role in disease 
pathogenesis on the basis of published in vitro and 
in vivo studies aimed at identifying the sites of 
modifications, the enzymes involved and the con­
sequences of modulating these modifications on 
the structure, aggregation, membrane binding 
and toxicity of a-syn. 
Phosphorylation 
Increasing evidence from pathologic, genetic, ani­
mal model, biochemical and biophysical studies 
suggests that phosphorylation of a-syn at one or 
multiple sites may play an important role in regulat­
ing its structure, membrane binding, oligomeriza­
tion, fibril formation, LB formation and 
neurotoxicity in vivo (Anderson et al., 2006; 
Fujiwara et al., 2002). The first evidence demon­
strating phosphorylation of a-syn emerged from 
immunohistochemical and biochemical studies by 
Iwatsubo and colleagues and was supported later 
by many studies. Using a phospho-specific antibody 
and mass spectrometry, they demonstrated that the 
majority of a-syn within LB and inclusions isolated 
from brains of patients who died of PD, multiple 
system atrophy (MSA), dementia with Lewy bodies 
(DLB) and other synucleinopathies is phosphory­
lated at serine 129 (S129-P) (Anderson et al., 2006; 
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Fig. 2. Most studied a-syn post-translational modifications reported on the basis of their identification in LB. All the modifications 
identified thus far, including phosphorylation, truncation, nitration and covalent cross-linking by tissue transglutaminase, occur at 
and/or involve the C-terminal region of the protein. Only ubiquitination (mono-, di- and tri-) is restricted to the lysine residues in the 
N-terminal region of the protein comprising residues 1–36. 
Fujiwara et al., 2002; Kahle et al., 2000; Okochi 
et al., 2000; Takahashi et al., 2003). Subsequent 
cell culture studies demonstrated that a-syn is con­
stitutively phosphorylated at S87 and S129. Since 
then S129-P has emerged as a defining hallmark of 
PD and related synucleinopathies (Anderson et al., 
2006; Fujiwara et al., 2002; Okochi et al., 2000; 
Takahashi et al., 2003) and is consistently observed 
in a-syn inclusion formed in cellular and animal 
models over-expressing WT or mutant a-syn 
(Chen and Feany, 2005; Lo Bianco et al., 2002; 
Neumann et al., 2002; Takahashi et al., 2003; 
Yamada et al., 2004). Recent studies from our 
group demonstrated that a-syn is phosphorylated 
at S87 in vivo and within LB. The level of S87-P is 
increased in brains of TG models of synucleinopa­
thies and human brains from Alzheimer’s disease 
(AD), DLB and MSA patients (Paleologou et al., 
2010). A recent report by Feany and colleague 
demonstrated that a-syn is also phosphorylated at 
tyrosine 125 (Y125-P) and that phosphorylation at 
tyrosine residues Y125, Y133 and Y135 suppresses 
Author's personal copy
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S129-P-induced aggregation and toxicity. These 
studies demonstrate the presence of multiple phos­
phorylation sites within a-syn and suggest potential 
cross-talk between the different modified sites. 
All potential phosphorylation sites in a-syn 
are highly conserved 
A close examination and comparison of the amino 
acid sequences of all synucleins from humans and 
other species reveals that the majority of potential 
a-syn phosphorylation sites (4 serine, 10 threonine, 
4 tyrosine residues,  Fig. 3b) are highly conserved in 
all species, suggesting that phosphorylation at one 
or multiple sites may play important roles in reg­
ulating a-syn function in health and disease. 
Considering all a-syn phosphorylation sites identi­
fied in vivo [S129 (Chen and Feany, 2005; Fujiwara 
et al., 2002), S87 (Paleologou et al., 2010) and Y125 
(Chen et al., 2009)] and in vitro [S87 (Kim et al., 
2006; Okochi et al., 2000); S129 (Chen and Feany, 
2005; Fujiwara et al., 2002; Kim et al., 2006; Okochi 
et al., 2000; Pronin et al., 2000; Takahashi et al., 
2003) and Y125, Y133 and Y136 (Ahn et al., 2002; 
Ellis et al., 2001; Nakamura et al., 2001; Negro 
et al., 2002; Takahashi et al., 2003)], it is striking 
that all these sites cluster at the C-terminal region 
of a-syn spanning residues 120–140. Only S87 lies 
in the hydrophobic NAC region of a-syn, which is 
essential for a-syn aggregation and fibrillogenesis 
(El-Agnaf et al., 1998). These findings suggest 
important roles for these modifications in regulat­
ing protein–protein, protein–ligand and protein– 
a 
b 
Fig. 3. a-syn phosphorylation in normal and pathological conditions. (a) Schematic depiction highlighting all the potential 
phosphorylation sites in a-syn: serine (S), threonine (T) and tyrosine (Y). When phosphorylation of the residue has been reported, 
the corresponding known kinases are indicated; the sites phosphorylated in human are listed in the upper part of the schema. 
(b) Multiple sequence alignment of a-syn generated by MUSCLE (version 3.6), in which serine, threonine and tyrosine residues are 
shown in color; note their high level of conservation trough mammals as only serine 87 is not preserved in rodents. 
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metal interactions, which have been mapped and 
shown to be mediated by the C-terminal domain of 
a-syn (see below). 
Unravelling the role of phosphorylation 
in modulating the physiological and pathogenic 
activities of a-syn requires identification 
of the kinases and phosphatases involved in 
regulating its phosphorylation in vivo 
Although the exact kinases and phosphatases 
responsible for regulating a-syn phosphorylation at 
S129 in vivo are still not known, a series of in vitro 
and cell culture-based studies have identified a num­
ber of kinases, which phosphorylate a-syn at S129 
and/or S87, including casein kinase I (CKI) (S87 and 
S129), casein kinase II (CKII) (S129) (Okochi et al., 
2000) and the G protein-coupled receptor kinases 
(GRKs 1, 2, 5 and 6; S129) (Pronin et al., 2000), 
LRRK2 (leucine-rich repeat kinase 2) (S129) 
(Qing et al., 2009) and PLKs (polo-like kinases) 
(S129) (Inglis et al., 2009; Mbefo et al., 2010) 
(Fig. 3a). Tyrosine phosphorylation has also been 
reported at Y125 by Fyn (Nakamura et al., 2001), 
Syk (Negro et al., 2002), Lyn (Negro et al., 2002), c-
Frg (Negro et al., 2002) and Src tyrosine kinases 
(Ellis et al., 2001), with Syk (Negro et al., 2002) 
also phosphorylating at Y133 and Y136. 
Phosphorylation at S129 and/or S87 alters 
the conformation of monomeric a-syn and 
inhibits its fibrillization in vitro 
Current cellular and in vivo studies aimed at dissect­
ing the functional consequences of phosphorylation 
at serine, threonine or tyrosine residues mainly rely 
on genetic approaches to block (e.g. replacing serine/ 
threonine with alanine, S/T ! A, or tyrosine with 
phenylalanine, Y ! F) or mimic constitutive phos­
phorylation (e.g. replacement of serine with gluta­
mate or aspartate, S ! E/D). The structural and 
electrostatic similarities between glutamate/aspar­
tate (net charge of –1) and phosphoserine (net charge 
of –2) suggest that this type of substitution represents 
a reasonable approach to mimic constitutive phos­
phorylation at specific serine residues. However, 
detailed studies from our group have shown that 
S ! D/E substitutions do not reproduce all aspects 
of phosphorylation. For example, structural compar­
isons of the phosphomimics S129D/E with S129-P 
using nuclear magnetic resonance (NMR) indicate 
that phosphorylation at S129 and S87 increases the 
hydrodynamic radius of a-syn to a value comparable 
to that observed for the WT protein in 8 M urea. In 
addition, paramagnetic relaxation enhancement of 
amide protons observed with the help of a spin 
label attached to residue 18 showed that long-range 
interactions between the N- and the C-terminal 
domains of a-syn are attenuated upon phosphoryla­
tion at S129 and S87. On the other hand, mutation of 
S129 and S87 to glutamate (S129E and S87E) or 
aspartate (S129D and S87D) does not lead to an 
extended conformation of monomeric a-syn. This 
result suggests that mutation of S ! D/E cannot 
fully mimic the effect of phosphorylation on the 
structure and dynamics of a-syn. The extent of fibril 
formation by the phosphomimics S129E/S129D is 
similar to that of the WT a-syn, whereas phosphor­
ylation at S129 (S129-P) consistently inhibits a-syn 
fibrillization. On the other hand, S ! D/E substitu­
tion at S87 reproduces the effect of phosphorylation 
on a-syn aggregation at this residue, that is both 
substitutions inhibit the fibrillization of a-syn in 
vitro. However, phosphorylation at S87, but not the 
S87D mutation, increases the hydrodynamic radius 
of a-syn and influences its binding to membranes. 
Together, these studies demonstrate that phosphor­
ylation of a-syn at S129 and/or S87 significantly inhi­
bits its aggregation (Paleologou et al., 2008, 2010; 
Waxman and Giasson, 2008) and that the S ! D/E 
substitutions do not reproduce all aspects of phos­
phorylation. Therefore, the results obtained with 
these mimics should be interpreted with caution. 
Does phosphorylation promote or prevent 
a-synuclein aggregation in vivo? 
To answer this question, one must be able to 
modulate the level of phosphorylation in vivo. 
Author's personal copy
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This modulation can be achieved by co-expression 
of a-syn and the relevant kinase or by comparing 
the effect of over-expressing the WT protein to 
the mutants designed to mimic (S129D) or abolish 
phosphorylation (S129A)(see Table 2). Although 
in vitro biophysical studies have clearly shown that 
replacement of serine by glutamate or aspartate 
does not reproduce all aspects of phosphorylation, 
the use of these mutants remains the only option 
for elucidating the role S129 phosphorylation in 
regulating a-syn aggregation and toxicity in vivo, 
especially given the lack of knowledge of efficient 
kinases that phosphorylate a-syn at this residue. 
In the next sections, we will present an overview 
of the findings from different in vivo studies aimed 
at elucidating the consequences of S129 
phosphorylation. 
GRK2-mediated phosphorylation at S129 
or substitution of serine with aspartate (S129D) 
promotes a-syn oligomerization but does not 
influence inclusion formation in rodent 
and Drosophila models of PD 
Initial studies aimed at investigating phosphoryla­
tion at S129 were carried out in Drosophila, a  
model in which a-syn expression induces a loss 
of dopaminergic neurons or retinal degeneration, 
depending on the promoter used (Feany and 
Bender, 2000). The co-expression of the Droso­
phila homologue of the kinase GRK2 with a-syn 
did not prompt or prevent the appearance of pro­
teinase K-resistant inclusions (Chen and Feany, 
2005), but it did enhance the formation of a-syn 
oligomers (Chen et al., 2009) compared to situa­
tions where only a-syn was over-expressed. These 
results suggest that increasing S129 phosphoryla­
tion does not promote a-syn fibrillization in vivo 
and argue in favour of the hypothesis that S129 
phosphorylation results in the kinetic stabilization 
and/or accumulation of toxic a-syn oligomers. 
What remains unclear is whether the over-
expression of GRK2 contributes to a-syn toxicity 
via mechanisms that are independent of a-syn 
phosphorylation. Further, the efficiency with 
which GRK2 phosphorylates a-syn and the turn­
over of S129-P was not investigated in these 
studies. 
To overcome the drawbacks associated with 
kinase over-expression, a complementary 
approach was used, based on the expression of 
the S129D or S129A variant. In Drosophila, 
over-expression of the phosphomimic variant 
(S129D) yielded results that are comparable to 
those obtained with GRK2 over-expression: (1) 
inclusion formation by S129D was similar to that 
observed for the WT protein and (2) S129D 
formed more oligomeric forms of a-syn than the 
WT protein. Similarly, in vitro studies using 
recombinant proteins demonstrated that fibril for­
mation by the phosphomimics S129D/S129E is 
similar to that of the WT protein. Together, 
these studies demonstrate that S ! D mutation 
at S129 alters the oligomerization, but not 
fibrillization, of a-syn. 
Substitution of serine 129 with alanine (S129A) 
promotes a-syn inclusion formation and 
fibrillization in vivo and in vitro, respectively 
Interestingly, in both the fly and the rodent 
models, the S129A mutants forms five times 
more insoluble, proteinase K-resistant inclusions 
(but fewer oligomers) than WT and S129D a-syn 
(Chen and Feany, 2005; Chen et al., 2009). 
In vitro, the S129A mutant forms fibrils more 
readily and to a greater extent than WT or the 
S129D mutant. Neither the S ! A nor the S ! E 
mutation alters the structure or morphology of 
a-syn fibrils in vitro. Initially, these findings 
appear to support the toxic hypothesis model, 
where accelerated fibrillization by this mutant 
ensures depletion of the toxic oligomers, thus 
explaining the reduced toxicity observed for 
S129A in the fly model. However, this correla­
tion between accelerated fibrillization and 
reduced toxicity did not hold consistently in 
various rodent models. 
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In rodent models, the effects of S ! D and S ! A 
substitutions on a-syn aggregation are variable 
In rodent, over-expression of S129D and S129A 
a-syn, using AAV-mediated gene transfer in the 
substantia nigra, led to inconsistent observations, 
partially due to the different approaches used to 
characterize and quantify a-syn aggregation. At 
first, Gorbatyuk et al. (2008) reported that both 
S129D and S129A form punctate a-syn aggregates 
in vivo. The authors described a-syn S129D immu­
nostaining in neuronal cytoplasm as heterogeneous, 
whereas WT or a-syn S129A immunolabelling was 
more evenly distributed throughout the cell, with­
out providing quantitative evaluation of the level of 
aggregation. Furthermore, neither the biochemical 
and structural properties of these aggregates nor 
the a-syn oligomerization in this model was thor­
oughly investigated, which precludes comparison of 
the extent and type of a-syn aggregation in other 
models. On the contrary, a detailed study by Azer­
edo da Silveira et al. (2009) provided experimental 
observations of aggregation that agreed with data 
obtained in Drosophila: a-syn S129A forms more 
b-sheet-rich (thioflavin S-positive), proteinase 
K-resistant aggregates than WT and S129D a-syn. 
Finally, a recent study (McFarland et al., 2009) 
described a-syn-positive deposits in dopaminergic 
neurons, but revealed similar aggregation patterns 
for all three proteins (WT, S129D and S129A 
a-syn). The discrepancy with the previous two 
models might be due to the fact that McFarland 
et al. (2009) used a bi-cistronic mRNA to co­
express a-syn and green fluorescent protein 
(GFP), which may lead to lower expression of a­
syn compared to classical monocistronic RNA. 
Recent reports suggest neuronal toxicity associated 
with AAV-mediated over-expression of GFP in the 
substantia nigra, which could mask the differences 
in terms of neuronal loss caused by a-syn and the 
two S129 mutants (Baens et al., 2006; Sawada  et  al.,  
2010; Ulusoy et al., 2009). An additional contribut­
ing factor might be the fact the immunohistological 
analysis was carried out 6 weeks after virus injec­
tion, compared to 8 weeks in the studies by 
Azeredo da Silveira et al. (2009) and Gorbatyuk 
et al. (2008). 
Does phosphorylation enhance or protect against 
a-syn toxicity? 
The accumulation of S129-P a-syn has been asso­
ciated repeatedly with disease states both in post­
mortem human brains (Fujiwara et al., 2002) and 
in various models of synucleinopathy (Lo Bianco 
et al., 2002; Neumann et al., 2002). However, the 
extent to which does S129 phosphorylation and/or 
the accumulation of a-syn S129-P represent toxic 
events in the pathogenesis of PD is not yet fully 
understood. In Drosophila, the co-expression of 
a-syn with the GRK2 homologue, as well as 
over-expression of a-syn S129D, accelerates neu­
ronal loss compared with WT a-syn or S129A 
alone (Chen and Feany, 2005), suggesting a toxic 
effect of a-syn S129-P. On the contrary, in a 
screening performed in yeast, aimed at identifying 
modulators of a-syn-induced toxicity, PLK2, 
which was recently shown to be an efficient kinase 
and a major contributor to S129 phosphorylation 
in vitro and in vivo, was shown to be protective 
(Mbefo et al., 2010). This finding was confirmed in 
two other models, Caenorhabditis elegans and pri­
mary cultures of rat mesencephalic neurons 
(Gitler et al., 2009). Studies from two independent 
groups based on the over-expression of the a-syn 
variants S129D and S129A in rat models support 
the hypothesis that a-syn S129-P is protective 
(Azeredo da Silveira et al., 2009; Gorbatyuk 
et al., 2008). Indeed, over-expression of a-syn 
S129A in rat substantia nigra was reported to be 
more toxic than when the WT protein or S129D 
mutants were over-expressed (Azeredo da 
Silveira et al., 2009; Gorbatyuk et al., 2008). The 
results from the two rat models support the 
hypothesis that phosphorylation of a-syn is pro­
tective. The following findings are consistent with 
this hypothesis: (1) PLK2 over-expression protects 
against a-syn-induced toxicity in yeast, C. elegans 
and primary rat neurons (Gitler et al., 2009) and 
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(2) disease-associated a-syn mutations (E46K and 
A30P) reduce the level of a-syn phosphorylation 
at S129 in cell culture and upon in vitro phosphor­
ylation with CK1 and PLK2 (Paleologou and 
Lashuel, unpublished data). However, a recent 
study by Hyman and colleagues reported a similar 
toxicity for the three variants (WT, S129D and 
S129A) (McFarland et al., 2009). As mentioned 
above, the results from this study might be biased 
by co-expression of GFP and a-syn (Baens et al., 
2006; Sawada et al., 2010; Ulusoy et al., 2009). 
Different mechanisms may be involved 
in modulating a-syn toxicity in the Drosophila 
and rodent models of PD 
Although the increased aggregation of S129A cor­
relates well with its enhanced toxicity in the rat 
model (Azeredo da Silveira et al., 2009), the oppo­
site was observed in the fly model, where the 
increased aggregation of S129A, relative to WT 
and S129D, correlates with protection against 
a-syn-induced toxicity (Chen and Feany, 2005) 
(see Table 2). These observations clearly indicate 
the involvement of different neuropathologic 
mechanisms between the two models and suggest 
that a direct correlation between aggregation and 
toxicity in the fly and rat models may not be possi­
ble, especially if different approaches are used to 
assess and quantify toxicity and aggregation in the 
different models. Furthermore, there is no evidence 
that the aggregation pattern and structure of the 
aggregates/inclusions formed in the two models are 
identical. Initial studies by Chen and Feany 
reported the absence of thioflavin S staining or 
proteinase K-resistant aggregates in conditions of 
neuronal loss, where the accumulation of such 
aggregates occurs and correlates with neuronal 
loss in the rat model. Furthermore, in the rat 
model, S129D, which tends to be neuroprotective, 
formed fewer but larger aggregates than a-syn 
S129A (Azeredo da Silveira et al., 2009). More 
recently, Feany and colleagues showed, by western 
blot, that a-syn-associated toxicity correlates with 
the accumulation of soluble high molecular weight 
oligomeric a-syn species. Therefore, a careful ana­
lysis of data obtained in Drosophila suggests that 
large aggregates are well handled and do not impair 
cell survival, while soluble oligomers could be the 
primary toxic species in flies. Unfortunately, similar 
biochemical studies have not been carried out in the 
rat model, so direct comparison of the degree of 
oligomer formation and accumulation between the 
two models is not possible. An alternative hypoth­
esis, which could account for the differential toxicity 
of inclusions between rat and fruit flies, relies on the 
fact that Drosophila is naturally devoid of a-syn, 
whereas a rat homologue does exist and bears 
strong sequence similarity to the human a-syn 
(>95%). Previous studies have shown that mouse 
and rat a-syn form fibrils more readily than human 
a-syn and influence the oligomerization and fibril­
logenesis of human a-syn. Whether the interactions 
between rat and human a-syn could explain the 
differences in toxicity between the rat and the fly 
models remains unknown. However, this hypoth­
esis can be tested by over-expressing a-syn, S129D 
or S129A in the substantia nigra of one of the a-syn 
knockout mouse models. 
Despite the differences, some consistent 
observations emerged from both models 
The effect of phosphorylation using the phospho-
mimicking approach has yielded different results 
depending on the host organism (fly vs. rat) and 
the methods employed to assess and/or quantify 
aggregation and toxicity (see Table 2). Despite 
the discrepancy in terms of a-syn toxicity in the 
different models, comparing the results obtained 
in the Drosophila and rat models reveal some con­
sistent observations. (1) In addition to blocking 
phosphorylation, substitution of serine with alanine 
enhances the aggregation of a-syn in both animal 
models and in vitro, based on quantitative analysis of 
a-syn solubility and thioflavin S labelling. (2) In both 
fly and rat models, S129D exhibits similar aggre­
gation properties as the WT protein (Azeredo da 
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Silveira et al., 2009; Chen and Feany, 2005). 
Interestingly, both observations are in complete 
agreement with in vitro biophysical studies using 
purified recombinant a-syn. These studies 
showed that a-syn S129A aggregates more 
rapidly than the WT protein (Paleologou et al., 
2008). Although the effects of these two muta­
tions (S ! A and S ! D) on a-syn aggregation 
are reproducible in these different models 
(Table 1), subsequent studies raised some con­
cern about their utility to model the phosphory­
lation state of the protein in vivo. A direct 
comparison of the structural and aggregation 
properties of monomeric S129D and S129-P, 
which was prepared by phosphorylating a-syn 
with CK1 or PLK2, demonstrated that phosphor­
ylation at S129 increases the conformational flex­
ibility of a-syn and strongly inhibits its 
fibrillization, whereas monomeric S129D exhibits 
structural and aggregation properties similar to 
those of the WT protein (Fig. 4c). Observations 
of intraneuronal deposits are often a good start­
ing point for assessing aggregation, but further 
analyses to characterize the solubility of struc­
tural properties (using electron microscopy, thio-
flavin S staining and proteinase K digestion) and 
oligomerization state (immunoblotting using 
denaturing and native gel electrophoresis) of a­
syn within these inclusions are crucial to deter­
mine accurately how phosphorylation affects a­
syn aggregation and to elucidate the relationship 
between a-syn aggregation and toxicity in vivo. 
What are the molecular mechanisms underlying 
phosphorylation-dependent a-syn toxicity? 
A limited number of studies have attempted to 
dissect the cellular mechanism associated with 
phosphorylation-dependent a-syn neurotoxicity 
in vivo. Using electron microscopy, Azeredo da 
Silveira et al. (2009) sought to examine subcellu­
lar abnormalities induced by enhancing or block­
ing a-syn phosphorylation. These studies 
revealed the presence of lysosomal bodies and 
phagosome-like structures trapped within the 
aggregates, suggesting an attempt by the neurons 
to degrade the inclusions by macroautophagy 
(Azeredo da Silveira et al., 2009). In addition, 
they reported the association of a-syn S129A 
with membranous structures, endoplasmic reticu­
lum (ER) and Golgi apparatus, mostly in the 
vicinity of aggregates; these observations sug­
gested an impairment of ER–Golgi trafficking 
by non-phosphorylated a-syn. On the contrary, 
in SH-SY5Y cells, over-expression of a-syn 
S129A or inhibition of CKII decreases the activa­
tion of ER stress and caspase 3 cleavage. This 
study also reported that the increase of S129-P 
a-syn levels, following rotenone treatment, is 
associated with activation of these pathways 
(Sugeno et al., 2008). Therefore, whether ER 
stress is due to a-syn or related to its phosphor­
ylation state remains to be determined. Azeredo 
da Silveira et al. (2009) suggested that Golgi–ER 
impairment results from a dysfunction of the 
Table 1. Consequences of mutations at position 129 of a-syn on its aggregation and on cell survival 
AGGREGATION SURVIVAL 
MODEL a-synS129A a-syn a-synS129D a-synS129A a-syn a-synS129D 
Rat Gorbatyuk et al., 2008 nd nd nd †† † – 
Rat Azeredo da Silveira ✹✹ ✹ ✹ †† † † 
et al., 2009 
Rat McFarland et al., 2008 ✹ ✹ ✹ † † † 
Drosophila Chen and Feany, 2005 ✹✹ ✹ ✹ – †  ††
nd: not determined; ✹: aggregation; †: cell death; –: no cell loss. 
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b 
Fig. 4. The phosphomimics S129D/E or S87E do not reproduce the effect of phosphorylation on the structural properties of 
monomeric a-syn. (a) Structural comparison of the residue serine, phosphoserine and glutamate illustrating the similarities 
between the two last species. (b) The hydrodynamic radius of a-syn and a-syn S129D in a phosphate buffer is similar, around 28A 
(black bar), while the radius increased to 35A after phosphorylation of a-syn either at both S87 and S129 (p-WT) or at S129 only 
(pS87A) (dashed bars). In all cases, the radii rose to 36A in the presence of urea (white bars) corresponding to a true random-coiled 
state. (c) Illustration of the conformations populated by a-syn, a-syn S129E and a-syn S129-P (S129-p, S87-p) and of the long-range 
interactions involved (from Paleologou et al., 2008). 
microtubule-mediated transport system, as indi­
cated by the disarrayed neurofilament network 
when a-syn S129A is over-expressed. In cell 
lines, phosphorylation at S129 induces microtu­
bule retraction (Kragh et al., 2009). Phosphory­
lated a-syn (S129-P) also co-localizes with 
activated caspase 9 in different models of synu­
cleinopathy (Fournier et al., 2009; Yamada et al., 
2004). It is worth notifying that activated caspase 
9 immunostaining is preferentially found in cells 
positive for S129-P, although this later category 
of cells represented only a minor subpopulation 
among neurons accumulating a-syn (Fournier 
et al., 2009).Over-expression of a-syn S129A or 
a-syn S129D in rat substantia nigra leads to acti­
vation of caspase 9 (Azeredo da Silveira et al.,  
2009), indicating that caspase activation occurs 
independent of S129 phosphorylation and is 
likely to be a consequence of a-syn expression. 
Novel phosphorylation sites 
Recent studies from the Feany’s laboratory and our 
group demonstrated that a-syn in vivo is phosphory­
lated at S87 and Y125. Studies by both groups sug­
gest that modifications at this site correlate with 
disease and significantly influence the oligomeriza­
tion and fibrillization of a-syn. The levels of S87-P 
were increased in brains of TG models of synuclei­
nopathies and human brains from AD, Lewy body 
disease (LBD) and MSA patients. Using antibodies 
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against phosphorylated a-syn (S129-P and S87-P), 
significant levels of immunoreactivity were detected 
in the membrane in the LBD, MSA and AD cases 
but not in normal controls. Given that the remaining 
potential phosphorylation sites in a-syn are highly 
conserved, it would not be surprising that these 
residues also undergo phosphorylation and may 
play a role  in  modulating the  physiologic and/or  
pathogenic properties of a-syn. Therefore, further 
studies, using phospho-specific antibodies targeting 
the different potential phosphorylation sites, are 
necessary to map all the phosphorylation sites in a­
syn and elucidate their role in regulating its struc­
ture, aggregation and function(s). 
Truncations 
Truncated a-syn species are present 
in the normal brain and aggregate with the 
full-length a-syn in PD and related disorders 
Biochemical characterization of aggregated a-syn 
from LBs revealed that it comprises predominantly 
full-length a-syn, in addition to small amounts of 
various truncated species with apparent molecular 
masses of 10–15 kDa (Anderson et al., 2006; Baba 
et al., 1998; Campbell et al., 2001; Crowther et al., 
1998; Li et al., 2005; Liu et al., 2005; Okochi et al., 
2000; Spillantini et al., 1998). At least five species 
were detected using mass spectrometry and repre­
sent C-terminal truncations (Fig. 5) (Anderson 
et al., 2006). A comparison between LB-derived 
and cytosolic a-syn forms showed that some trun­
cated species were exclusively observed in the a­
syn derived from LB. The cleavage sites were deter­
mined by tryptic digestion and sequencing using 
liquid chromatography followed by mass spectro­
metry (LC-MS/MS). Species terminating at D-115 
(a-syn-D115), D-119 (a-syn-D119), N-122 (a-syn­
N122), Y-133 (a-syn-Y133) and D135 (a-syn­
D135) were identified (Fig. 5) (Anderson et al., 
2006). Three additional truncated forms of a-syn 
were also identified in samples from PD, DLB and 
MSA brain tissues: two C-terminal truncated forms 
(ending approximately between amino acid resi­
dues 102–125 and 83–110, respectively) and a third 
N- and C-terminal truncated isoform, which were 
only detectable in aggregated forms of a-syn 
(Li et al., 2005; Liu et al., 2005; Tofaris et al., 2003). 
Interestingly, these isoforms are present in healthy 
and diseased brains, suggesting that a-syn trunca­
tion occurs under physiologic conditions. The most 
striking difference is that PD and DLB extracts 
contained appreciable amounts of truncated a-syn 
in SDS- and urea-soluble fractions and a significant 
level of the N- and C-terminal truncated forms 
(Li et al., 2005; Liu et al., 2005). All together, these 
observations show that a-syn truncation occurs 
under normal conditions and suggest that the trun­
cated a-syn may have a normal physiologic role. 
These findings also suggest that the C-terminal trun­
cated forms that accumulate selectively in LBs or 
insoluble fractions aggregate more readily and could 
act as effective seeds to accelerate the aggregation of 
the full-length protein. 
C-terminal truncations promote the fibrillization 
of a-syn in vitro 
Among the various post-translational modifications 
identified to date, the C-terminal deletion variants of 
a-syn consistently exhibit higher fibrillization pro­
pensity relative to the WT full-length protein. These 
findings, combined with the observation obtained 
for C-terminal deletion variants of a-syn in human 
brains and brains of TG animal models of PD 
(Li et al., 2005), led to the hypothesis that proteolytic 
processing of the C-terminus could be responsible 
for the initiation of a-syn fibrillogenesis in PD, pos­
sibly via a seeding mechanism. Lee and colleagues 
also reported several naturally occurring C-terminal 
deletion variants (including amino acids 1–119 or 
1–122) in a-syn over-expressing TG mice and pro­
posed that proteolytic processing of the C-terminus 
of a-syn may play a critical role in the initiation of 
a-syn aggregation and fibrillogenesis in vivo. 
The effect of proteolytic cleavage on the aggre­
gation of a-syn has been extensively investigated 
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Fig. 5. Truncation of a-syn in vivo and in vitro. (a) In the upper part of the schema are represented the known sites of truncation of 
a-syn identified in extracts from LB (black arrows; Anderson et al., 2006) or from brain tissue of PD cases (pink arrows; Li et al., 
2005, Liu et al., 2005). Last residue is indicated, or, when not defined, a range is given. Various enzymes able to cleave a-syn 
monomer or fibrils have been described; their site of digestion is indicated in the lower part of the schema. (b) Representation of the 
truncated forms studied in TG mice (upper part; Tofaris et al., 2006, Wakamatsu et al., 2008, Daher et al., 2009) and Drosophila 
(lower part; Periquet et al., 2007). 
using recombinant proteins and by over-expres­
sing C-terminal deletion variants in cell lines. 
In vitro fibrillization studies have consistently 
shown that truncation of various segments of the 
C-terminal residues 110–140 enhances the rate of 
a-syn aggregation and fibrillogenesis. Some 
fragments (1–110; 1–120) promote nucleation 
(Hoyer et al., 2004) and seed the aggregation of 
full-length a-syn (Li et al., 2005; Murray et al., 
2003). Serpell et al. (2000) reported that 1–87 a­
syn aggregates more rapidly than 1–120 a-syn and 
rat a-syn, which aggregates faster than human a­
syn (Rochet et al., 2000). Similarly, studies by 
Murray et al. (2003) showed that the C-terminal 
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truncated a-syn variants 1–89, 1–102, 1–110, 1–120 
and 1–30 aggregated more rapidly than the full-
length protein with the 1–110 variant showing the 
most robust enhancement of a-syn fibril forma­
tion. Interestingly, the 1–102 and 1–110 variants, 
but not 1–120, seed the fibrillization of the full-
length protein in vitro. Together, the results from 
these studies combined with data from solid-state 
NMR (Bertini et al., 2007; Wu et al., 2008), and 
immunogold labelling of a-syn fibrils (Murray 
et al., 2003) suggest that fibril formation by a-syn 
is mediated by its N-terminal domain (~1–90), 
whereas the C-terminal region remains flexible 
and may play a role in inhibiting the aggregation 
of monomeric a-syn (Murray et al., 2003). Subse­
quent NMR studies provided further evidence in 
support of this hypothesis and demonstrated that 
the C-terminal domain participates in long-range 
interactions with the N-terminal region of a-syn. 
These interactions shield the hydrophobic regions 
within the protein and prevents its self-assembly 
(Bertoncini et al., 2005; Pawar et al., 2005). Sev­
eral groups have also shown that the C-terminal 
20–30 amino acids, which are highly anionic, inhi­
bit fibrillization (Crowther et al., 1998; Kim et al., 
2002; Tofaris et al., 2006). This inhibition is 
mediated by transient interactions between the 
C-terminal region and the amyloidogenic NAC 
region. Truncations of residues in this region or a 
charge-neutralizing effect (e.g. by divalent metals 
such as Ca2þ and Cu2þ and polyamines) may 
account for the fibril acceleration by cations, 
including polyamines and C-terminal deletion 
mutants of a-syn (Antony et al., 2003; Cohlberg 
et al., 2002; Goers et al., 2003) and certain metals 
(Paik et al., 1999; Uversky et al., 2001; Yamin 
et al., 2003). 
Several enzymes have been implicated 
in the proteolysis of a-syn 
Although the inhibitory activity of the C-terminal 
sequence suggests that proteolytic cleavage of this 
region could promote the fibrillization of a-syn in 
vivo, a protease that selectively cleaves this 
sequence has not been identified. A number of 
enzymes have been implicated in a-syn cleavage 
and generation of truncated fragments. Neurosin, 
a trypsin-like serine protease, was detected in LBs 
(Iwata et al., 2003; Ogawa et al., 2000). The in 
vitro cleavage of a-syn by neurosin generates 
one major fragment 1–80, which does not aggre­
gate in vitro (Iwata et al., 2003) and three minor 
ones: 1–97, 1–114 and 1–121 (Kasai et al., 2008) 
(Fig. 5). Interestingly, the phosphorylated form 
(S129-P) and the disease-associated mutants 
(A30P and A53T) are more resistant to proteoly­
sis by neurosin (Kasai et al., 2008). 
The intracellular calcium-dependent protease 
calpain cleaves monomeric WT or mutant (A30P 
and A53T) a-syn at several sites within the NAC 
region to yield fragments that inhibit the aggrega­
tion of the full-length protein (Mishizen-Eberz 
et al., 2003, 2005) (Fig. 5). The major generated 
fragments consist of two N-terminally truncated 
fragments, 58–140 and 84–140, and four C-termin­
ally truncated forms, 1–57, 1–73, 1–75 and 1–83 
(Mishizen-Eberz et al., 2003). Furthermore, using 
N-terminal sequencing and an antibody against 
the N-terminal truncated a-syn, Dufty et al. 
(2007) reported another calpain cleavage site 
between the residues 9 and 10. In the fibrillar 
state, calpain-mediated cleavage occurs exclu­
sively within the C-terminal region (residues 114 
and 122) (Mishizen-Eberz et al., 2005), probably 
due to this region remaining flexible and exposed 
to proteases. Calpain-cleaved a-syn species were 
found in LB and Lewy neurites in diseased brain 
and co-localize with activated calpain, suggesting a 
link between a-syn proteolysis by this enzyme and 
a-syn aggregation and pathology (Dufty et al., 
2007). 
Recently, a lysosomal enzyme, cathepsin D was 
reported to generate two forms of C-terminally 
truncated a-syn detectable at 12 and 10 kDa, 
respectively (Sevlever et al., 2008; Takahashi 
et al., 2007). Using antibodies to different a-syn 
epitopes, the authors demonstrated that these 
fragments end approximately between the 
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residues 91–98 and 91–115, respectively (Sevlever 
et al., 2008; Takahashi et al., 2007). Sevlever et al. 
(2008) also demonstrated that cathepsin-gener­
ated a-syn fragments are the major component 
of oligomeric a-syn species formed under oxida­
tive stress. The formation of these correlated with 
an increase of CKII expression and a-syn phos­
phorylation in cell culture. These observations 
suggest a possible relationship among a-syn trun­
cation, phosphorylation and oligomerization when 
cells are exposed to oxidative stress. 
Although ubiquitin-mediated degradation of a­
syn has been proposed by several studies, a-syn 
was reported to undergo proteolytic cleavage by 
the proteasome, in the absence of ubiquitination 
(Tofaris et al., 2001). The caspase-like activity of 
the 20S proteasome generates four a-syn frag­
ments corresponding to 1–73, 1–83, 1–110 and 
1–119 (Lewis et al., 2010;  Liu et al., 2005). In vitro 
aggregation assay showed that the 1–110 and 
1–120 a-syn fragments aggregate more rapidly 
than the full-length and can seed the aggregation 
and formation of hybrid protofibrils of truncated 
and non-truncated a-syn (Lewis et al., 2010; Liu 
et al., 2005). The PD-linked mutations do not 
significantly affect the cleavage of a-syn by the 
proteasome (Lewis et al., 2010); however, the 
fragments containing the mutation A53T aggre­
gated more rapidly than the truncated WT and 
full-length A53T and were shown to seed and 
accelerate the aggregation of the full-length pro­
tein (Liu et al., 2005). 
The matrix metalloproteases (MMPs, e.g. 
MMP-1 and MMP-3), a family of zinc-dependent 
endopeptidases, also cleave a-syn and generate 
several C-terminally truncated fragments in vitro 
(1–54, 1–57, 1–79 and 1–78) (Levin et al., 2009; 
Sung et al., 2005). Levin and collaborators showed 
that a-syn in vitro aggregation is increased after a 
limited proteolysis by MMPs. However, higher 
MMP concentrations resulted in an inhibition of 
a-syn aggregation (Levin et al., 2009), most likely 
due to increased MMP-mediated cleavage within 
the NAC region, which is essential for a-syn oli­
gomerization and fibril formation. 
Truncation (in vivo studies) 
To explore in vivo the effect of C-terminal trunca­
tions on the aggregation and toxicity of a-syn, TG 
flies and mice over-expressing various truncated 
forms of a-syn have been generated (see Table 2). 
In Drosophila, two different truncations have been 
investigated: a-syn 1–87, corresponding to a non­
natural truncation with the entire acidic C-terminal 
domain was deleted and a pathological truncation, 
a-syn 1–120, with the last C-terminal amino acids 
removed (Periquet et al., 2007). The 1–87 a-syn 
variant did not aggregate or induce toxicity when 
expressed in Drosophila, although expression at 
levels similar to that of the WT a-syn could not be 
reached, which may account for these observations. 
Conversely, the pan neuronal expression of a-syn 
1–120 resulted in the appearance in the Drosophila 
brain, of more abundant oligomers and a-syn­
positive, proteinase K-resistant inclusions as com­
pared to the full-length protein expressed at similar 
levels. The formation of inclusions by a-syn 1–120 
was accompanied by a loss of dopaminergic neu­
rons, which occurred slightly faster for the trun­
cated than for the full-length a-syn. 
Three different TG mice have been produced, 
expressing truncated variants of a-syn under the 
control of the TH or nestin promoter. The first 
TG mice were generated in a strain devoid of 
endogenous a-syn; the expression level of a-syn 
1–120 was lower than what is expected for the 
rodent protein (Tofaris et al., 2006). Dopaminergic 
neurons from the olfactory bulbs and from the 
substantia nigra presented some a-syn-positive 
fibrillar inclusions (thioflavin S-positive). Despite 
the fact that expression of 1–120 resulted in the 
formation of both non-fibrillar and fibrillar a-syn 
aggregates, no neuronal loss was observed at 12 
months of age, although DA and homovanilic 
acid (HVA) levels were decreased in 3-month-old 
animals. Wakamatsu et al. (2008) generated TG 
mice that over-express either the pathogenic 
mutant A53T or a truncated variant of this mutant 
in catecholaminergic neurons comprising residues 
1–130 (a-syn A53T, 1–130). The expression of 
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Table 2. Animal models looking at consequences of truncation and phosphorylation on a-syn aggregation and toxicity 
PTM Aggregation method Toxicity method 
studied Model Strategy of assessment of assessment Publication(s) 
a-syn 1-87 
a-syn 1-120 
Drosophila 
Drosophila 
Mouse 
Pan neuronal 
Promoter 
Pan neuronal 
Promoter 
TH promoter (a-syn 
KO background) 
n.d. 
þ
IHC (a-syn) PK 
digestion and 
HMW by WB 
þ
IHC (a-syn) 
e-microscopy Thio S 
– 
Number of TH neurons 
þ
Number of TH neurons 
– 
Number of TH neurons 
DA decreased at 3 
months 
Periquet et al. 
(2007) 
Periquet et al. 
(2007) 
Tofaris et al. 
(2006) 
Michell et al. 
(2007) 
a-syn 1-119 Mouse Inducible 
expression (TH- or 
nestion-promoter) 
– 
IHC (unpublished) 
– 
Number of TH neurons 
DA decreased at 12 
Daher et al. 
(2009) 
months with TH 
a-syn A53T 
1-130 
a-syn 
S129-P 
Mouse 
Yeast 
TH promoter 
a-syn þPLK2 
– 
IHC (a-syn) 
n.d. 
promoter 
þ
number of TH neurons 
(developmental defect) 
– 
PKK2 suppressed a-
Wakamatsu et al. 
(2008a, 2008b) 
Gitler et al., 
(2009) 
C. elegans a-syn þ PLK2 n.d. 
syn-induced cell death 
– 
PLK2 suppressed a-
Gitler et al. 
(2009) 
Drosophila a-synþGRK2 
pan neuronal or eye 
targeting promoter 
a-syn S129D 
pan neuronal or eye 
targeting promoter 
– 
PK digestion 
but 
HMW in WB 
– 
IHC (a-syn) PK 
digestion Solubility 
but HMW in WB 
syn-induced cell death 
þ
Number of TH neurons 
Ommatidia disruption 
þ
number TH neurons 
ommatidia disruption 
Chen and Feany 
(2005) 
Chen et al. 
(2009) 
Rat 
a-syn S129A 
pan neuronal or eye 
targeting 
a-syn S129D 
CBA promoter 
a-syn S129A 
CBA promoter 
þ
IHC (inclusions) PK 
digestion Solubility 
þ
IHC (a-syn) 
– 
IHC (a-syn) 
– 
Number of TH neurons 
Ommatidia disruption 
– 
Number of TH neurons 
þ
Number of TH neurons 
DA decrease 
Gorbatyuk et al. 
(2008) 
Rat a-syn S129D 
CMV promoter 
a-syn S129A 
CMV promoter 
– 
ThioS staining 
PK digestion 
e-microscopy 
þ
ThioS staining 
PK digestion 
e-microscopy 
– 
Number of TH neurons 
þ
Number of TH neurons 
Azeredo da 
Silveira et al. 
(2008) 
(Continued ) 
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Table 2. (Continued ) 
PTM Aggregation method Toxicity method
 
studied Model Strategy of assessment of assessment Publication(s)
 
Rat	 a-syn S129D 
GFP co-expressed 
CBA promoter 
a-syn S129A 
GFP co-expressed 
CBA promoter 
a-syn Y125- Drosophila a-syn Y125F, 
P, Y133-P, Y133F, Y136F 
Y136-P pan neuronal or eye 
targeting promoter 
a-syn þ shark 
pan neuronal 
promoter 
– 
IHC (a-syn, ubi) 
– 
IHC (a-syn, ubi) 
n.d. 
but HMW by WB 
n.d. 
but reduced HMV 
by WB 
– McFarland et al.
 
Number of TH neurons (2009)
 
DA level
 
– 
Number of TH neurons 
DA level 
þ Chen et al. 
(2009) 
Number of TH neurons 
ommatidia disruption 
– 
Number of TH neurons 
Shark reduced a-syn­
induced cell death 
In various model over-expressing a-syn, the appearance of a-syn S129-P deposits correlates with the development of ubiquitin immunoreactivity, 
proteinase K-resistant and thioflavine S-positive inclusions. n.d.: no data; þ: present; -: absent; CBA: CMV beta-actin; CMV: cytomegalovirus; DA: 
dopamine; Dopac: 3,4-dihydroxyphenylacetic acid; e- microscopy: electron microscopy; GFP: green fluorescent protein; HVA: homovanilic acid; HMW: 
high molecular weight species; IHC: immunohistochemistry; KO: knockout; PK: proteinase K; TH: tyrosine hydroxylase positive; Thio S: thioflavine S 
staining; ubi: ubiquitin; WB: western blot. 
exogenous a-syn ranged from 1.3- to 1.6-fold the 
level of the endogenous protein. When the A53T 
1–130 variant was over-expressed, the animals dis­
played a developmental decrease in the number of 
dopaminergic neurons from the substantia nigra, 
while animals expressing the full-length a-syn A53 
did not present any defect. No abnormal proteinac­
eous accumulations were detected in the affected 
brain regions, despite the fact that the absence of 
endogenous a-syn was expected to promote aggre­
gation (Wakamatsu et al., 2008). Finally, Daher 
et al. (2009) described the consequences of Cre­
dependent expression of the C-terminal truncation 
a-syn 1–119. The authors did not observe any 
protein deposition by immunohistochemistry or 
neuronal loss, although dopamine, 3,4-dihydroxy­
phenylacetic acid and HVA were decreased in the 
striata of 10-month-old mice; the low protein level 
likely explains this mild phenotype, as the expres­
sion of a-syn 1–119 was 10-fold lower than that of 
the endogenous protein. 
The toxicity of the C-terminal truncated forms 
of a-syn was also assessed using in vitro cell death 
assays. The addition of hybrid protofibrils, com­
prising truncated (1–110 or 1–120) and full-length 
a-syn, significantly increased a-syn-induced toxi­
city in SH-SY5Y neuroblastoma compared to the 
addition of monomeric truncated or full-length a­
syn separately (Li et al., 2005). These data suggest 
that truncated a-syn may enhance cell death by 
promoting the formation of toxic protein aggre­
gates (Liu et al., 2005). Co-over-expression of the 
C-terminal fragments (1–110 and 1–120) and the 
full-length protein also enhanced a-syn-induced 
cell death by increasing the cell vulnerability to 
oxidative stress (Li et al., 2005; Liu et al., 2005). 
The emerging results from the various studies 
discussed above demonstrate that C-terminal trun­
cated a-syn aggregates more than the full-length 
protein in Drosophila, but the results from TG 
mice are variable. Indeed, while Tofaris et al. 
(2006) reported the accumulation of fibril and non-
fibrillar 1–120 a-syn inclusions, Wakamatsu et al. 
(2008) did not report the formation of any deposits 
of the A53T 1–130 variant, despite the fact that this 
mutant aggregates more than the full-length protein 
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in vitro. The discrepancies might be due to the lack 
of endogenous a-syn in the experiment by Tofaris 
et al. (2006). In vitro studies suggest that the pre­
sence of endogenous a-syn is expected to interfere 
with the fibrillization of human a-syn in the rat and 
mouse models. Consistent with this hypothesis, 
fibrillar aggregates were observed in mouse and fly 
models that do not express human a-syn (Chen and 
Feany, 2005; Tofaris et al., 2006). C-terminal trunca­
tions slightly increase neuronal loss compared to the 
normal a-syn in Drosophila, but not in two out of 
three TG mouse models. For comparison, pre­
viously published studies in mouse, targeting expres­
sion of full-length WT or PD-associated a-syn 
mutants (A30P & A53T) into dopaminergic neu­
rons with the TH-promoter, report no neuronal 
loss (Matsuoka et al., 2001), or a age-associated 
neurodegeneration at 19 months in the cases of 
A30P and A53T (Richfield et al., 2002; Thiruchel­
vam et al., 2004). Only expression of a-syn 1–130 
provoked a strong phenotype, with impaired devel­
opment of neurons from the substantia nigra pars 
compacta. However this model does not reproduce 
the progressive cell loss or the associated neuro­
pathology characteristic of synucleinopathies. 
Ubiquitination 
Ubiquitin-positive inclusions 
are a neuropathologic hallmark of PD 
and related disorders 
Several neuropathologic studies have shown that a 
large proportion of LBs present in the substantia 
nigra, the locus coeruleus, the hippocampus and 
the cortex of brain with PD and related disorders, 
are positive for a-syn (Baba et al., 1998; Spillantini 
et al., 1997, 1998) and ubiquitin (Gomez-Tortosa 
et al., 2000; Hasegawa et al., 2002; Kuzuhara et al., 
1988; Lowe et al., 1988; Manetto et al., 1988; 
Sampathu et al., 2003; Tofaris et al., 2003) 
(Fig. 6). Double-immunostaining using anti-a-syn 
and anti-ubiquitin antibodies revealed that the core 
of LBs is immunoreactive for both proteins and is 
surrounded by a rim of a-syn (Gomez-Tortosa 
et al., 2000; Mezey et al., 1998) (Fig. 6c). Other 
intra-cytoplasmic inclusions, larger than LB and 
without halo, called pale bodies, are positive for 
a-syn but only occasionally for ubiquitin (Gomez-
Tortosa et al., 2000; Tofaris et al., 2003). a-Synu­
clein and ubiquitin co-staining is also frequent in 
Lewy neurites (e.g. in the hippocampus) (Gomez-
Tortosa et al., 2000). Moreover, a-syn and ubiqui­
tin show extensive co-localization in the glial cyto­
plasmic inclusions in MSA. 
Biochemical analysis of purified LBs and/or LB-
derived preparations, using western blotting and 
mass spectrometry techniques, confirmed that 
some of the a-syn within LBs is ubiquitinated 
(Anderson et al., 2006; Hasegawa et al., 2002; Sam­
pathu et al., 2003; Tofaris et al., 2003). Interest­
ingly, the majority of a-syn species found in LB 
are mono- or di-ubiquitinated. Some tri-ubiquiti­
nated a-syn species have been detected by western 
blots, but no polyubiquitin chains were detected on 
a-syn isolated from LB or other brain tissues 
(Anderson et al., 2006; Hasegawa et al., 2002; Non-
aka et al., 2005; Sampathu et al., 2003). These find­
ings suggest that ubiquitination of a-syn may be 
involved in regulating some of its pathophysiologic 
properties and imply that ubiquitin-mediated 
degradation is not likely to be the major physiolo­
gical mechanism for degrading a-syn. Consistent 
with this hypothesis, Tofaris et al. (2001) demon­
strated that non-ubiqutinated a-syn can be 
degraded by the proteasome. Furthermore, studies 
from several groups have implicated other protein 
clearance pathways in the degradation and turn­
over of a-syn, including lysosomal and autophagic 
pathways (Cuervo et al., 2004; Vogiatzi et al., 2008; 
Webb et al., 2003; Xilouri et al., 2008). 
E3 ubiquitin-protein ligases implicated 
in the ubiquitination of a-syn 
Three E3 ubiquitin-protein ligases have been iden­
tified to play an important role in the ubiquitination 
of a-syn in vitro and in vivo: Parkin, ubiquitin 
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Fig. 6. Ubiquitin, a hallmark of LB, covalently modifies a-syn. Ubiquitin immunostaining in a nigral (a) and a cortical (b) LB (arrow) 
from synucleopathies diseased brains. (adapted from Chu et al., 2000). (c) Co-immunofluorescent labelling of a-syn and ubiquitin 
showing their co-localization in a LB from the substantia nigra of a PD patient: the staining shows ubiquitin and a-syn in the core of 
this inclusion and the a-syn alone in the periphery. Scale bar = 10 mm (adpated from Mezey et al., 1998). (d) Schematic representation 
of a-syn showing the lysine which can be ubiquitynated and the major sites of ubiquitination identified in LB (upper part; Anderson 
et al., 2006) or in cell culture and in vitro studies (lower part; Nonaka et al., 2005, Rott et al., 2008). 
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carboxy-terminal hydrolase L1 (UCH-L1) and 
seven in absentia homologue (SIAH) (Lee et al., 
2008; Liani et al., 2004; Rott et al., 2008). Interest­
ingly, the genes coding for Parkin and UCH-L1 are 
linked to familial forms of PD and to PD suscept­
ibility, respectively (Liu  et al., 2002;  Shimura  et al.,  
2000). Both Parkin and SIAH have been detected 
in LBs in PD brains (Bandopadhyay et al., 2005; 
Liani et al., 2004) 
Ubiquitination sites 
Ubiquitination of a-syn occurs at multiple lysine 
residues and the sites of ubiqutination depend on 
the conformational and/or aggregation state of the 
protein. There are 15 lysine (K) residues in a-syn, 
the majority of which are distributed within the 
N-terminal repeat sequences. The remaining resi­
dues are K80, K96, K97 and K103 (Fig. 6). Using 
single-site mutagenesis of lysine residues (K ! R) 
and enzyme (lysyl endopeptidase AP1) digestion 
followed by peptide mapping using mass spectro­
metry, different groups have identified the possi­
ble lysine residues in a-syn that undergo 
ubiquitination in vitro and in vivo. In vitro ubiqui­
tination of recombinant a-syn revealed that the 
monomeric and fibrillar forms of a-syn undergo 
ubiquitination at distinct lysine residues. In vitro, 
monomeric a-syn undergoes ubiqutination at sev­
eral lysine residues including K10, K21, K23, K32, 
K34, K43 and K96, with the major ubiquitin-con­
jugated sites represented by K21, K23, K32 and 
K34 (Nonaka et al., 2005; Rott et al., 2008). Muta­
tion of these residues to argnine (R) results in a 
>90% reduction of ubiquitinated a-syn (Nonaka 
et al., 2005). Similar results were obtained when 
these mutants were expressed in cell lines. Ubiqui­
tination of recombinant a-syn using rabbit reticu­
locytes fraction II or rat brain extracts revealed 
similar ubiquitination patterns with K21 and K23 
being the major ubiquitination sites (Nonaka 
et al., 2005). Interestingly, ubiquitination of 
a-syn fibrils prepared from recombinant a-syn, 
under identical conditions, occurs predominantly 
at K6, K10 and K12 (Nonaka et al., 2005). This 
observation may be explained by the fact that in 
a-syn fibrils, the N-terminal region remains acces­
sible for interaction with ubiquitin-protein ligases. 
The ubiquitination sites linked to PD and related 
disorders have been identified form LB-purified 
a-syn. Using trypsin digestion followed by LC­
MS/MS analysis, Anderson et al. (2006) identified 
residues K12, K21 and K23 as a major sites of 
ubiquitination in a-syn. 
Does ubiquitination of a-syn enhance 
or prevent its aggregation and toxicity? 
While the role of ubiquitination in modulating a­
syn aggregation in vivo remains poorly under­
stood, it is not essential for inclusion formation 
in vivo, as evidenced by the fact that not all a-syn 
inclusions in TG mouse models are ubiquitinated 
(Sampathu et al., 2003; van der Putten et al., 
2000). The role of ubiquitination in modulating 
a-syn aggregation and toxicity was addressed by 
investigating the in vitro ubiquitination of recom­
binant a-syn, in cell culture and TG animal 
model. In the animal models, attempts to modu­
late the level of a-syn ubiquitnation, and thereby 
attenuate a-syn-induced neurotoxicity, were 
based on the  regulation  of Parkin expression or 
the over-expression of ubiquitin. In Drosophila 
(Haywood and Staveley, 2004; Yang et al., 2003), 
Parkin over-expression protects against a-syn­
induced toxicity without modifying a-syn levels. 
Recently, Lee and collaborators demonstrated 
that the over-expression of ubiquitin has no 
effect per se on overall adult retinal or dopami­
nergic neuronal structure or viability (Lee et al., 
2009), but co-expression of ubiquitin and a-syn 
suppresses a-syn-induced motor impairment 
(negative geotactic locomotor response) and cell 
degeneration in Drosophila eyes and in the DM1 
cluster of dopaminergic neurons. Furthermore, 
the authors demonstrated that expression of 
the K48R, and not K63R ubiquitin mutants, 
suppresses the protective effect of ubiquitin 
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(Lee et al., 2009), suggesting that the ubiquitin­
mediated neuroprotective effect is potentially 
dependent on the K48 polyubiquitin linkage, a 
signature targeting proteins for proteasomal 
degradation (Lim et al., 2005). Together, these 
data suggest that a-syn ubiquitination could pro­
tect against a-syn toxicity in Drosophila PD mod­
els, by targeting a-syn for proteasomal 
degradation and enhancing the function of the 
ubiquitin proteasome system. 
In a rat model, over-expressing Parkin protects 
against a-syn toxicity without affecting a-syn 
levels (Lo Bianco et al., 2002). Unfortunately, 
none of the reported studies in fly and rat models 
characterized the amount of ubiquitinated a-syn 
or attempted to map the site of modification and/ 
or characterize the ubiquitination pattern of a-syn. 
In TG mice over-expressing a-syn, the knockout 
of the parkin gene does not modify a-syn quantity 
(Fournier et al., 2009; Stichel et al., 2007; von 
Coelln et al., 2006) or levels of ubiquitinated a­
syn (von Coelln et al., 2006). However in one of 
these models, the levels of S129-P a-syn deposits 
that are ubiquitinated decreased in the absence of 
Parkin (Fournier et al., 2009). But the same study 
showed, by in vitro ubiquitination, that neither a­
syn nor S129-P a-syn is a Parkin substrate, sug­
gesting that the fibrils rather than the monomeric 
protein might be ubiquitinated by Parkin. The 
decreased ubiquitination of S129-P a-syn inclu­
sions is associated with a delayed appearance of 
the neurodegenerative phenotype, indicating a 
possible toxicity of Parkin-mediated ubiquitina­
tion. On the one hand, this report agrees with 
data describing a lack of synergy between Parkin 
deficiency and a-syn over-expression (von Coelln 
et al., 2006) and the previously described protec­
tive effect of Parkin expression against a-syn­
induced toxicity (Haywood and Staveley, 2004; 
Lo Bianco et al., 2002; Petrucelli et al., 2002; 
Yang et al., 2003). On the other hand, these results 
are in agreement with data showing that ubiquiti­
nation of a-syn by SIAH promotes the formation 
of cytotoxic inclusions (Rott et al., 2008). To con­
clude, the limited studies reported in the literature 
indicate that Parkin does not modulate a-syn 
levels, but it might be involved in its deposition 
in vivo. Whether the ubiquitinated aggregates are 
toxic or protective is still controversial and 
requires further investigations. 
In cell culture, endogenous SIAH co-localizes 
with a-syn and is, in part, responsible for its mono 
and di-ubiquitination in mammalian cell lines and 
human neuroblastoma, since the suppression of 
SIAH expression using shRNA completely 
abolishes a-syn ubiquitination (Lee et al., 2008; 
Rott et al., 2008). Moreover, the co-expression of 
a-syn and SIAH enhances a-syn mono and di­
ubiquitination (Lee et al., 2008; Rott et al., 
2008). Co-expression of a-syn, an E3 ubiquitin­
protein ligase (Siah-1) and ubiquitin results in 
the formation of predominantly mono and di-ubi­
quitinated a-syn species (Lee et al., 2008). Siah-1­
or Siah-2-mediated ubiquitination enhances the 
aggregation of a-syn and formation of a-syn-posi­
tive inclusion in PC12 cells and SH-SY5Y human 
neuroblastoma (Lee et al., 2008; Rott et al., 2008). 
In vitro ubiquitination of a-syn by SIAH promotes 
the formation of higher molecular weight a-syn 
aggregates as determined by western blot analysis 
(Rott et al., 2008). This observation suggests that 
ubiquitination by SIAH may enhance a-syn aggre­
gation in vitro. These findings were confirmed by 
electron microscopy studies showing that SIAH­
ubiquitinated a-syn forms more aggregates than 
the non-ubiquitinated form (Rott et al., 2008). 
Interstingly, the SIAH-ubiquitinated a-syn was 
reported to enhance the aggregation of non-ubi­
quitinated a-syn (Rott et al., 2008), suggesting that 
ubiquitinated a-syn may promote aggregation by 
seeding the non-ubiquitinated forms. The impact 
of the phosphorylation and the disease-linked 
mutations on a-syn ubiquitination in vitro is 
minor (Nonaka et al., 2005; Rott et al., 2008). 
A30P and 453T mutations reduce the ability of 
a-syn to bind to SIAH (Lee et al., 2008) but they 
do not disrupt the efficiency of the ubiquitination 
(Rott et al., 2008). 
The formation of ubiquitinated inclusions asso­
ciated with cell death after the inhibition of the 
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proteasome system in neuronal cell culture and 
in vivo has been reported by several groups 
(McNaught et al., 2002, 2004; Rideout and Stefa­
nis, 2002). Inhibition of the proteasome or impair­
ment of UCH-L1 activity induced neuronal 
degeneration and an increased intracellular 
expression of a-syn and ubiquitin (McNaught 
et al., 2002; Rideout and Stefanis, 2002). After 
12 h incubation with proteasome inhibitors, 
intracellular inclusions immunoreactive for a-syn, 
ubiquitin and the chaperone Hsp70 were detected 
in the apoptotic cells (McNaught et al., 2002; 
Rideout and Stefanis, 2002). Interestingly, 
McNaught and collaborators highlighted the vul­
nerability of the dopaminergic versus the 
GABAergic neurons to proteasome inhibition 
(McNaught et al., 2002), which they suggested 
could explain the specific degeneration of the 
nigral dopaminergic neurons in PD. Similar 
observations were reported in differentiated and 
undifferentiated PC12 neuroblastoma after the 
inhibition of the proteasome (Rideout et al., 
2001). Lactacystin-exposed cells showed diffuse 
ubiquitin immunoreactivity, and in some other 
cells, focal cytoplasmic accumulation of ubiquitin 
immunoreactivity was detected (Rideout et al., 
2001). It is noteworthy that not all the ubiquitin 
inclusions were positive for a-syn. This observa­
tion suggests that the accumulation of a-syn within 
the intracellular inclusion depends on the cell 
type. In a rat model, McNaught showed that the 
impairment of the proteasome by systemic expo­
sure to proteasome inhibitors induced the devel­
opment of progressive parkinsonism, neuronal 
degeneration in different brain regions including 
the substantia nigra and the formation of LB-like 
inclusions positive for a-syn and ubiquitin 
(McNaught et al., 2004). Together, the data 
generated from the proteasome inhibition models 
show that the formation of the ubiquitin and 
a-syn-positive inclusions could be associated with 
neuronal toxicity in vivo and in vitro. However, 
whether the a-syn in these inclusions is ubiquiti­
nated and which residues are implicated remain to 
be elucidated. 
Conclusions 
Significant advances have been made towards the 
identification of post-translational modifications 
of a-syn (Fig. 7). To date, several post-translational 
modifications have been identified, some of which 
appear to be strongly linked to the pathology in 
PD and related synucleinopathies (e.g. phosphor­
ylation). Although the results from the studies 
discussed above demonstrate that introducing 
these modifications into a-syn or mutating the 
site of modification influences the structure and/ 
or aggregation properties of the protein, reconcil­
ing the effects of these modifications in the dif­
ferent model systems is complicated by several 
factors: (1) different mechanisms of toxicity may 
be involved in modulating a-syn aggregation and 
toxicity in different model organisms (e.g. Droso­
phila vs. rodents); (2) differences in the methods 
used to assess aggregation and toxicity and lack 
of standardized rigorous approaches for the ana­
lysis of soluble and aggregated forms of a-syn, 
particularly in cellular and animal models, which 
have made it difficult to make direct comparisons 
between the various studies; (3) mutations that 
are generally used to mimic post-translational 
modifications do not truly reproduce all aspect 
of these modifications (e.g. use of phosphomi­
mics; see below); (4) the majority of the in vivo 
studies focused primary on the effect of modifica­
tions on a-syn aggregation and toxicity (Table 2) 
and very little on elucidating the molecular 
mechanisms and cellular pathways altered by 
these modifications and (5) the cross-talk 
between different modifications is currently diffi­
cult to reproduce and study in vitro or in vivo. 
Recent studies suggest that a-syn is phosphory­
lated at multiple sites, and phosphorylation at 
tyrosine residues modulates a-syn aggregation 
and toxicity induced by S129-P, highlighting the 
importance of investigating the interplay between 
the different post-translational modifications. 
These challenges, combined with the lack of 
good cellular and animal models that reproduce 
the pathology and neuronal loss in humans, have 
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Fig. 7. Effects of a-syn post-translational modifications on its properties. 
limited our ability to translate the knowledge 
gained from the identification of these modifica­
tions to an improved understanding of the 
molecular mechanisms underlying a-syn toxicity 
and developing new therapies for PD and related 
disorders. Therefore, several key outstanding 
questions concerning the role of post-transla­
tional modifications in PD remain unanswered 
(see Box 1). 
Looking beyond aggregation 
The majority of a-syn modifications were initially 
identified and implicated in disease pathogenesis 
solely on the basis of isolation and/or co-localiza­
tion of modified a-syn within LBs or inclusions 
from diseased brains or TG animal models. There­
fore, studies on these modifications have focused 
primarily on their role in modulating a-syn aggre­
gation and toxicity rather than their effect on the 
functional and physiologic properties of the pro­
tein, including its stability, subcellular localization, 
membrane interactions and clearance mechanisms 
(Fig. 7). Post-translational modifications of pro­
teins represent important molecular switches for 
regulating protein–protein and protein–ligand 
interactions and thus protein function in health 
and disease. The C-terminal region of a-syn has 
been implicated in the majority of a-syn interac­
tions with proteins (Fernandez et al., 2004; Gias­
son et al., 2003; Jensen et al., 1999) and metal ions 
(Brown, 2007; Paik et al., 1999). Therefore, trun­
cation and/or phosphorylation at single or multi­
ple sites is likely to influence a-syn affinity to 
proteins, metals and other ligands (e.g. dopamine 
and polyamines) and alter the biochemical and 
biological processes regulated by its interaction 
with these molecules. For example, a-syn interacts 
with the microtubule-associated protein tau and 
stimulates tau phosphorylation (Jensen et al., 
1999) and fibrillogenesis (Frasier et al., 2005) 
both in vitro and in vivo. The tau binding 
site was mapped to the C-terminal region (AA 
87–140) of a-syn. Phosphorylation at S129, but 
not Y125, was also reported to reduce the rate of 
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Box 1 
1.	 What percentage of a-syn is modified in vivo and is there a correlation between the level of 
modified a-syn and disease progression? With the exception of phosphorylation of a-syn at 
S129, quantitative assessments of the levels of modified a-syn in the soluble and aggregated 
states of the proteins, relative to total a-syn, are lacking. Studies by Iwatsubo and colleagues 
suggest that >90% of a-syn within LBs is phosphorylated at S129. 
2.	 Do these modifications occur before and/or after a-syn aggregation and LB formation? For all 
reported modifications, it remains unclear whether the presence of modified a-syn in LB and other 
inclusions reflects their active role in the initiation of a-syn aggregation and development of 
pathology or a cellular response aimed at clearing unmodified forms of a-syn within LB. 
Interestingly, all disease-associated modifications, with the exception of phosphorylation at S87, 
occur at flexible regions that remain accessible in the monomeric, oligomeric and fibrillar states of 
a-syn. Recent findings that phosphorylation of a-syn at serines (S87 and S129) and tyrosines (Y125, 
Y133 and Y136), covalent cross-linking by tissue transglutaminase and nitration all inhibit a-syn 
fibril formation in vitro support the notion of these post-translational modifications being a late 
event rather than a prerequisite for a-syn aggregation. 
3.	 What is the effect of each modification on the structure of monomeric a-syn and its binding to 
membranes, oligomerization and fibrillogenesis? The answer to this question lies in our ability to 
introduce site-specific modifications in a-syn and produce the desired protein in sufficient 
quantities to perform structural and biophysical studies. These site-specific modifications may not 
be possible at this stage in vivo but are achievable at the protein and single-cell level. Recent 
advances in chemistry have made it possible to introduce site specifically single or multiple post­
translational modifications into proteins. A detailed structural understanding of how these 
modifications alter the structural properties and dynamics of monomeric a-syn will provide 
important insight into their role in triggering or inhibiting a-syn aggregation and/or interactions 
with other proteins and cellular compartments. 
4.	 What is the effect of each modification on the stability, degradation and functional properties of 
a-syn? Only an integrative interdisciplinary approach with standardized methods and measures for 
assessing changes in a-syn properties would bring us closer to addressing the key outstanding 
mechanistic questions on the role of a-syn post-translational modifications in PD and translate this 
knowledge into novel therapies. 
5.	 Is there cross-talk between the different post-translational modifications in a-syn? Thus far, all the 
modifications of a-syn have been investigated separately, and studies aimed at elucidating the 
interdependence and relationship between the different modifications are lacking. Different forms 
of a-syn are modified at multiple sites. Phosphorylation at Y125, ubiquitination or C-terminal 
truncations co-exist with S129-P, although the sequence of modification remains unknown. More 
importantly, the residues involved in these modifications are in close proximity to each other and 
result in a dramatic change in the structure and aggregation of monomeric a-syn. Therefore, it is 
clear that modifications at these residues will likely have a dramatic effect on a-syn interactions 
with other enzymes and susceptibility to modifications by these enzymes. 
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6.	 What are the natural enzymes involved in regulating each of these modification? Selective and 
efficient site-specific modification of a-syn at single or multiple sites in vivo are currently not 
possible because the identity of the natural enzymes (e.g. kinases, phosphatases, E3 ubiquitin 
ligases, hydrolyases and proteases) responsible for regulating the dynamics of these modifications 
remain unknown. The existing tools and methods (e.g. the use of phosphomimics or expression of 
truncated a-syn variants) do not allow for investigating the effect of post-translational modification 
with spatial and temporal resolution. Several candidate enzymes have been implicated in the 
phosphorylation and proteolysis of a-syn and are currently being tested and validated as 
potential therapeutic targets. The identification and validation of enzymes that regulate specific 
a-syn post-translational modifications will provide more effective means for modulating the level of 
these modifications and determining their role in disease pathogenesis in vivo, using genetic 
manipulations and/or small molecule inhibitors of these enzymes. Furthermore, this knowledge 
will allow us to identify the cellular pathways regulating these modifications, which may yield more 
effective therapeutic targets. 
7.	 Can we prevent a-syn aggregation and toxicity in vivo by modulating the type and extent of post­
translational modification at specific residue(s)? To be able to answer this question, we must use 
approaches and tools that allow site-specific modulation of post-translational modifications in vivo. 
Although the identification of candidate enzymes involved in regulating these modifications 
represents a first important step, it is crucial to demonstrate that the effect of modulating the 
activity of these enzymes is mediated specifically by a-syn, more effective means for modulating the 
level of these modifications and determining their role in disease pathogenesis in vivo using genetic 
manipulations and/or small molecule inhibitors of these enzymes. Furthermore, this knowledge will 
allow us to elucidate the cellular pathways in regulating these modifications, which may yield more 
tractable therapeutic targets and pathways. 
a-syn transport (Saha et al., 2004). Together, 
these findings suggest that reversible phosphoryla­
tion or truncations within the C-terminal region 
(Y125 or S129) may be involved in regulating the 
association/dissociation with tau and other neuro­
nal proteins (e.g. tau, synphilin (Lee et al., 2004), 
phospholipase D (PLD) (Payton et al., 2004; Pro­
nin et al., 2000), 14-3-3 (Ostrerova et al., 1999), 
metals (Liu et al., 2005) and lipids. Phosphoryla­
tion within the C-terminal region (S129 or Y125) 
or the incorporation of phosphorylation mimick­
ing mutations at these residues also reportedly 
reduces membrane binding and blocks a-syn­
mediated inhibition of PLD2 (Okochi et al., 
2000; Payton et al., 2004; Pronin et al., 2000), an 
enzyme involved in the hydrolysis of phosphati­
dylcholine and vesicular trafficking. 
Recent studies by McFarland and colleagues 
demonstrated that phosphorylation at S129 and 
Y125 constitute an important switch for regulating 
a-syn interaction with other proteins. They 
explored the role of phosphorylation at S129 or 
Y125 in protein–protein interactions involving 
a-syn by comparing the protein–protein interac­
tions of phosphorylated and non-phosphorylated 
C-terminal peptides encompassing these residues 
(residues 101–140) using pull down assays and 
mass spectrometry (McFarland et al., 2008). 
Their studies showed great differences in the set 
of proteins pulled down by phosphorylated forms 
of a-syn. The phosphorylated peptides showed 
preferential interactions with pre-synaptic cytos­
keletal proteins and proteins involved in synaptic 
vesicle endocytosis, subunits of serine/threonine 
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kinases and phosphatases, whereas the non-phos­
phorylated peptide interacted preferentially with 
mitochondrial electron transport chain complexes. 
Some of the proteins reported to interact with 
a-syn [e.g. 14-3-3 and microtubule-associated pro­
tein 1B (MAP1B)] show a preference to the phos­
phorylated state (S129-P) of a-syn. 
The NAC region in a-syn plays an important 
role in mediating a-syn fibrillization (Paleologou 
et al., 2010; Waxman and Giasson, 2008), mem­
brane binding (Lotharius and Brundin, 2002) and  
interactions with other proteins, such as the 
enzyme PLD2 (Payton et al., 2004). Recent stu­
dies from our laboratory show that S87 phosphor­
ylation alters the conformation of membrane-
bound a-syn and decreases its affinity to lipid 
vesicles, but does not abrogate binding, probably 
by destabilizing the helical conformation and 
decreasing the lipid-binding affinity of the protein 
around the phosphorylation site. Together, these 
findings underscore the fact that elucidating the 
role of post-translational modifications in the 
pathogenesis of a-syn will require a better under­
standing how these modifications alter the phy­
siologic and functional properties of the protein 
and how potential cross-talk between the differ­
ent modifications influences the function of a-syn 
in health and disease. Only an integrative inter­
disciplinary approach with standardized methods 
and measures for assessing changes in a-syn prop­
erties would bring us closer to answering the 
key outstanding mechanistic questions regarding 
the role of a-syn post-translational modification 
in PD and translate this knowledge into novel 
therapies. 
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